Fractyl Health (NASDAQ:GUTS) Upgraded by Craig Hallum to “Strong-Buy” Rating

Craig Hallum upgraded shares of Fractyl Health (NASDAQ:GUTS) to a strong-buy rating in a research note issued to investors on Wednesday morning,Zacks.com reports.

Several other equities research analysts have also recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a report on Thursday, June 4th. Wall Street Zen upgraded Fractyl Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Fractyl Health in a research report on Tuesday, May 12th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a report on Thursday, March 26th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Fractyl Health currently has an average rating of “Moderate Buy” and a consensus price target of $5.12.

Fractyl Health Stock Performance

NASDAQ:GUTS opened at $0.79 on Wednesday. Fractyl Health has a 52-week low of $0.38 and a 52-week high of $2.44. The firm has a market cap of $124.86 million, a price-to-earnings ratio of -0.61 and a beta of 2.29. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.28 and a current ratio of 4.28. The business’s fifty day moving average is $0.78 and its 200 day moving average is $0.97.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.17) by $0.23. Research analysts predict that Fractyl Health will post -0.6 EPS for the current year.

Insider Buying and Selling at Fractyl Health

In related news, Director Ian Sheffield purchased 35,000 shares of Fractyl Health stock in a transaction on Wednesday, June 10th. The stock was acquired at an average price of $0.73 per share, for a total transaction of $25,550.00. Following the completion of the transaction, the director directly owned 35,000 shares in the company, valued at $25,550. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director William Bradley acquired 68,493 shares of the company’s stock in a transaction dated Wednesday, June 10th. The stock was acquired at an average cost of $0.73 per share, with a total value of $49,999.89. Following the purchase, the director owned 84,622 shares of the company’s stock, valued at approximately $61,774.06. This trade represents a 424.66% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 171,493 shares of company stock valued at $127,150 over the last 90 days. 8.52% of the stock is currently owned by company insiders.

Institutional Trading of Fractyl Health

Several institutional investors and hedge funds have recently modified their holdings of GUTS. Nantahala Capital Management LLC purchased a new position in shares of Fractyl Health during the third quarter valued at $19,298,000. 683 Capital Management LLC increased its position in Fractyl Health by 30.1% during the 4th quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company’s stock valued at $13,305,000 after buying an additional 1,397,620 shares in the last quarter. Marshall Wace LLP raised its position in shares of Fractyl Health by 234.9% in the 4th quarter. Marshall Wace LLP now owns 5,926,745 shares of the company’s stock valued at $13,039,000 after purchasing an additional 4,156,969 shares during the last quarter. Pale Fire Capital SE lifted its stake in shares of Fractyl Health by 84.5% during the first quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock worth $2,711,000 after buying an additional 2,711,103 shares during the period. Finally, Alyeska Investment Group L.P. acquired a new stake in Fractyl Health during the 3rd quarter worth about $8,981,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.